

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

To:

see form PCT/ISA/220

PCT

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1)

		Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet)	
Applicant's or agent's file reference see form PCT/ISA/220		FOR FURTHER ACTION See paragraph 2 below	
International application No. PCT/US2004/036955	International filing date (day/month/year) 04.11.2004	Priority date (day/month/year) 04.11.2003	
International Patent Classification (IPC) or both national classification and IPC A61K39/395, A61P35/00			
Applicant CHIRON CORPORATION			

9-17-05

1. This opinion contains indications relating to the following items:

- Box No. I Basis of the opinion
- Box No. II Priority
- Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- Box No. IV Lack of unity of invention
- Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- Box No. VI Certain documents cited
- Box No. VII Certain defects in the international application
- Box No. VIII Certain observations on the international application

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

9-17-05

9-4-05

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA:	Authorized Officer
 European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Wagner, R Telephone No. +49 89 2399-7357
	

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITYInternational application No.
PCT/US2004/036955

IAP20 Rec'd PCT/PTO 03 MAY 2006

Box No. I Basis of the opinion

1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
 This opinion has been established on the basis of a translation from the original language into the following language , which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
 - a. type of material:
 a sequence listing
 table(s) related to the sequence listing
 - b. format of material:
 in written format
 in computer readable form
 - c. time of filing/furnishing:
 contained in the international application as filed.
 filed together with the international application in computer readable form.
 furnished subsequently to this Authority for the purposes of search.
3. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:
see separate sheet

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US2004/036955

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

the entire international application,
 claims Nos. 1-28 (regarding industrial applicability)

because:

the said international application, or the said claims Nos. 1-28 (regarding industrial applicability) relate to the following subject matter which does not require an international preliminary examination (specify):
see separate sheet

the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):

the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

no international search report has been established for the whole application or for said claims Nos.

the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:

the written form

has not been furnished
 does not comply with the standard

the computer readable form

has not been furnished
 does not comply with the standard

the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.

See separate sheet for further details

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/US2004/036955

**Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or
Industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes: Claims	1-28
	No: Claims	
Inventive step (IS)	Yes: Claims	1-28
	No: Claims	
Industrial applicability (IA)	Yes: Claims	-
	No: Claims	

2. Citations and explanations

see separate sheet

Re Item I

Basis of the report

No sequence listing in electronic form has been provided. As the written sequences appear to be identical to those of the parallel applications filed on the same date by the applicant (US04/36957, US04/37152, US04/36958, US0437159), the electronic version of the sequences of said parallel applications were used for search.

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 1-28 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Reference is made to the following documents:

D1: WO02/060485

D2: US5801227

D3: WO95/17202

D4: US5874082

D5: WO96/18413

2. All claims are directed to methods for treating solid tumours by using human antibodies CHIR-5.9 or CHIR-12.12 or antibodies having the same specificity. Said antibodies are directed against CD40 and are free of significant agonist activity. The subject-matter of all claims is novel (Article 33(2) PCT) because the prior art does not

disclose said antibodies.

In the prior art D1 discloses that anti-CD40 antibodies can be used in the treatment of sarcomas or carcinomas (page 26, lines 5-10). D1 does however not disclose whether said antibodies should have antagonist properties or not. On page 24, lines 9-10, D1 refers to several patents as references for anti-CD40 antibodies. D1 does not specify whether the anti-CD40 antibodies should have agonist properties or not. D1 refers to D2 which discloses the antibody HuCD40-M2. In D3 from the same applicant as D2, said antibody is further defined as having agonist properties because it was shown to have the same effect as soluble CD40-ligand. D1 refers also to D4, which discloses antagonist anti-CD40 antibodies. In another patent (D5) the use of an agonist antibody (mAb G28.5) in the treatment of carcinoma is disclosed (page 5). The prior art does neither disclose the use anti-CD40 antibodies, lacking agonist properties, in the treatment nor give any clear indication regarding the said use. D5 clearly points in a different direction and the experimental data of the present application show that the antagonist antibodies inhibit the growth of colon carcinoma in T-cell deficient nude mice (page 72). Therefore an inventive step can be acknowledged for the subject-matter of claims 1-28 (Article 33(3) PCT).